Innoviva, Inc. · NASDAQ:INVA
Innoviva — Investor Presentation (May 2023)
22 slides from Innoviva's investor presentation, May 24, 2023
Slide 1: Corporate Presentation May 2023
Corporate Presentation May 2023
Slide 2: Forward-looking statements
Forward-looking statementsThe information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Act"). Such forward looking statements i
Slide 3: Innoviva at a glance
Innoviva at a glance 3 1. Strongly cashflow - positive, durable core royalty business stemming from widely used respiratory products 2. Commercial stage, growth - oriented critical care and infectious disease assets supported by late - stage pipeline 3. Diversified, valuable portfolio of healthcare
Slide 4: Diversified, valuable portfolio of royalties and other healthcare assets
Innoviva has a diversified, valuable portfolio of royalties and other healthcare assets Royalty assets Innoviva Specialty Therapeutics assets Strategic healthcare assets Durable royalty stream from two widely used, differentiated respiratory products marketed by GSK RELVAR ® / BREO ® ELLIPTA ® ANORO
Slide 5: Royalty Assets
Royalty Assets 5 Our royalty assets, composed of widely used respiratory therapies commercialized by GSK, have produced durable, resilient revenues that are de - risked via geographic and drug class diversification 1. Projections per analyst consensus on GSK forecast website accessed May 10, 2023; G
Slide 6: Relvar/Breo and Anoro protected by an IP estate with meaningful remaining exclusivity
Relvar/Breo and Anoro are protected by an IP estate with meaningful remaining exclusivity 6 1. US patent 7,439,393. Original expiration 9/11/2022, granted additional exclusivity to 2025 through 35 USC § 156 2. US patents 9,750,726 and 11,090,294 3. US patent 8,746,242 4. US patent 9,763,965 Manufact
Slide 7: Acquisitions of Entasis and La Jolla formed a robust, growing commercial business
7 Our recent acquisitions of Entasis Therapeutics and La Jolla Pharmaceutical Company formed a robust, growing commercial business supported by an attractive late - stage pipeline Septic or other distributive shock Complicated intra - abdominal infections Hospital - acquired and ventilator - associa
Slide 8: XACDURO addresses serious infections with significant unmet need
8 XACDURO is an important therapy to address serious infections for which there is a significant unmet need 1. Antimicrobial Resistance Collaborators Lancet 2022; 399: 629 – 55 2. Kaye et al. Lancet Infect Dis . 2023 May 11:S1473 - 3099(23)00184 - 6 About XACDURO XACDURO is the first pathogen - targ
Slide 9: GIAPREZA's mechanism of action enables rapid vasoconstriction
9 GIAPREZA’s mechanism of action enables rapid and effective vasoconstriction for critically ill patients Results from pivotal ATHOS - 3 trial 2 About GIAPREZA GIAPREZA is a vasoconstrictor approved to increase blood pressure in adults with septic or other distributive shock More than 150K shock pat
Slide 10: XERAVA is a broad spectrum, potent antibiotic
10 XERAVA is a broad spectrum, potent antibiotic that addresses ESBL and other resistance related to overreliance on carbapenems and beta lactams Results from pivotal Phase 3 trials 1 XERAVA is a tetracycline - class antibiotic indicated for the treatment of complicated intra - abdominal infections
Slide 11: Therapeutic assets are a key value driver
Therapeutic assets are a key value driver providing excellent growth potential and significant embedded operating leverage 11 • The pressing need for novel therapeutics is becoming a serious global threat , especially for drug resistant infections • Historical underinvestment exacerbated development
Slide 12: Minority investments in high growth areas
Minority investments in high growth areas • Strategic equity investments in high - potential healthcare companies with significant promise ISP Fund providing further exposure to healthcare • $300M initially committed to ISP Fund in Dec 2020 primarily to public equity investments in healthcare in are
Slide 13: Innoviva has actively deployed capital to maximize shareholder value
Innoviva has actively deployed capital to maximize shareholder value 13 Return of capital to shareholders Repurchased GSK’s 32% equity stake for $392M and initiated $100M share repurchase program Opportunistic asset monetization Monetized Innoviva’s share of TRELEGY® royalties for $282M upfront, add
Slide 14: Innoviva has robust financials with multiple sources of value
Innoviva has robust financials with multiple sources of value 14 1. Includes revenues prior to Innoviva’s acquisition of La Jolla Pharmaceutical Note: Numbers shown for the twelve months ending March 31, 2023, unless otherwise noted $250M Anoro & Breo Royalty Revenue (LTM) $144M Cash and Cash Equiva
Slide 15: Management and board have world-class expertise in healthcare
Innoviva’s management and board have world - class expertise in healthcare 15 Innoviva Team Superior capabilities and network Unique and complementary skill sets Strong value creation focus Proven track record of success Relevant experience Management Team Pavel Raifeld, Chief Executive Officer Expe
Slide 16: Thank you
Thank you Investor contact: Innoviva@argotpartners.com Media contact: InnovivaMedia@grcomms.com
Slide 17: Appendix
Appendix
Slide 18: Relvar / Breo detail
17 Relvar / Breo detail: First once - daily inhaled corticosteroid / long - acting beta - agonist for asthmaand chronic obstructive pulmonary disease Net global sales ($B) RELVAR ® / BREO ® ELLIPTA ® (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder) Indications (US) • Long - term
Slide 19: Anoro detail
0.3 0.4 0.6 0.7 0.7 0.7 0.6 0.6 0.6 0.6 0.6 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 18 Anoro detail: Best - in - class long - acting beta - agonist / long - acting muscarinic antagonist for COPD 1. Projections per analyst consensus on GSK forecast w
Slide 20: Zoliflodacin is a novel, promising drug candidate
Zoliflodacin is a novel, promising drug candidate in an area of unmet medical need 19 About Zoliflodacin Compelling results from Phase 2 trial Zoliflodacin is a novel orally administered antibiotic developed for the treatment of uncomplicated gonorrhea Gonorrhea is one of the most commonly diagnosed
Slide 21: Armata is an innovator in anti-infectives
Armata is an innovator in anti - infectives addressing significant unmet medical need Armata is a clinical - stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic - resistant and difficult - to - treat bacterial infect
Slide 22: Additional minority portfolio investments
Additional minority portfolio investments 21 1. Paroxysmal atrial fibrillation 2. Immuno - oncology InCarda focuses on cardiovascular diseases; its lead drug is in late - stage development for PAF 1 ImaginAb is a leader in radio - pharmaceutical imaging with a differentiated solution for IO 2 patien